Get started
Author

David Doležil

Observed names: D Dolezil, D. DOLEZIL, D. Dolezil, D. Doležil, David Dolezil, Doležil, David
OpenAlex ID: A5012269428
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
2017 · Stewart Tepper, Messoud Ashina, et al. · The Lancet Neurology · 722
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
2018 · Messoud Ashina, Stewart Tepper, et al. · Cephalalgia · 143
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
2020 · Messoud Ashina, David Doležil, et al. · Cephalalgia · 131
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
2020 · Stewart J Tepper, Messoud Ashina, et al. · Cephalalgia · 106
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
2019 · Messoud Ashina, David Kudrow, et al. · Cephalalgia · 68
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
2022 · Patricia Pozo-Rosich, Holland C. Detke, et al. · Current Medical Research and Opinion · 43
PDF
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
2021 · Uwe Reuter, Christian Lucas, et al. · Advances in Therapy · 39
PDF
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives
2024 · Patricia Pozo-Rosich, David Dolezil, et al. · JAMA Neurology · 37
PDF
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
2019 · Jan Lewis Brandes, Hans-Christoph Diener, et al. · Cephalalgia · 33
PDF
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine
2024 · Stewart J. Tepper, David W. Dodick, et al. · JAMA Neurology · 27
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
2018 · Maria Trojano, Helmut Butzkueven, et al. · Multiple Sclerosis and Related Disorders · 19
PDF
One-Year Treatment with Galcanezumab in Patients with Chronic Migraine: Results from the Open-Label Phase of the REGAIN Study (P2.10-010)
2019 · Holland Detke, Patricia Pozo-Rosich, et al. · Neurology · 15
Cerebrospinal fluid and serum prealbumin (transthyretin) in patients with multiple sclerosis (MS): Comparison of particular subgroups of MS patients
2009 · M. Hybeľová, J. Svatoňová, et al. · Folia Microbiologica · 10
Immunophenotypic analysis of cerebrospinal fluid cell populations with the Cell‐Dyn Sapphire haematology analyser: method feasibility and preliminary observations
2008 · P. ADAM, O. SOBEK, et al. · International Journal of Laboratory Hematology · 9
Cryptococcal meningitis — a follow-up study of a serious clinical entity: quick cytological and microbiological diagnostics using a special staining procedure in cerebrospinal fluid specimens
2009 · P. Adam, O. Sobek, et al. · Folia Microbiologica · 6
Physiotherapy as an immunoactive therapy? A pilot study.
2012 · Kamila Rasova, David Dolezil, et al. · PubMed · 5
Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
2022 · Messoud Ashina, Stewart J. Tepper, et al. · Headache The Journal of Head and Face Pain · 4
Eosinophilic meningitis — an immunophenotyping recording of a very rare clinical entity — Brief Report
2009 · P. Adam, O. Sobek, et al. · Folia Microbiologica · 4
The International Classification of Headache Disorders (ICHD-3) – the official Czech translation
2020 · Tomáš Nežádal, Jana Marková, et al. · Česká a slovenská neurologie a neurochirurgie · 3
Hypnic headache - a rare primary headache disorder with very good response to indomethacin.
2012 · David Dolezil, Charis Mavrokordatos · PubMed · 3
Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study
2025 · Stewart J. Tepper, David W. Dodick, et al. · European Journal of Neurology · 2
Analysis of Injection Site Reactions across Four Placebo Controlled Trials of Erenumab for Migraine Prevention (P4.116)
2018 · Julio Pascual, David Doležil, et al. · Neurology · 2
An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study
2020 · David Dolezil, Jolana Markova, et al. · Journal of Pain Research · 1
PDF
Assessment of the Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine (P1.10-016)
2019 · Stewart J. Tepper, Messoud Ashina, et al. · Neurology · 1
Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study (S52.002)
2017 · Stewart Tepper, Katherine Widnell, et al. · Neurology · 1
Works count: 54
Citation count: 1,438
H-index: 12
I10-index: 13
Year
Topic
Type